US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
GFT Technologies SE (0O2W) 銘柄情報

GFT Technologies SE (0O2W)

7.5575

0.00

(0.00%)

終了 6月29日 12:30AM

GFT Technologies SE (0O2W) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

7.5575

( - )

買値

7.37

売値

7.745

出来高

261

0.00 日の範囲 0.00

7.5575 52 週間の範囲 7.5575

時価総額

前日終値

7.5575

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

65,228 €

発行済株式数

25,564,808

配当利回り

0.5 (2.31%)

PER

15.94

1 株当たり利益 (EPS)

1.34

歳入

895.89M

純利益

34.39M

GFT Technologies SE, together with its subsidiaries, provides digital transformation services. It operates in two segments in the Americas, the UK & APAC; and Continental Europe. The company offers Wynxx, a GenAI powered software delivery, Smaragd, a regulatory compliance suite, and Engenion, a proj... GFT Technologies SE, together with its subsidiaries, provides digital transformation services. It operates in two segments in the Americas, the UK & APAC; and Continental Europe. The company offers Wynxx, a GenAI powered software delivery, Smaragd, a regulatory compliance suite, and Engenion, a project portfolio management. It also provides services including AI services, AI consulting, data services, cloud services, software engineering, infrastructure and application management, and platform modernization. GFT Technologies SE has a strategic partnership with INTEC Industrie-Technik GmbH to advance the modernization and sustainment of mission-critical systems for defense organizations through sovereign, operationally ready AI.The company serves clients in investment and retail banking, insurance, and industrial sectors. GFT Technologies SE was founded in 1987 and is headquartered in Stuttgart, Germany. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.gft.com

本社

Stuttgart, Germany

設立

1987

GFT Technologies SE is listed in the sector of the ロンドン証券取引所 with ticker 0O2W. The last closing price for GFT Technologies was 7.56 €. Over the last year, GFT Technologies shares have traded in a share price range of 7.5575 € to 7.5575 €.

GFT Technologies currently has 25,564,808 shares in issue. The market capitalisation of GFT Technologies is 193.21 € million. GFT Technologies has a price to earnings ratio (PE ratio) of 15.94.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	7.5575	7.5575	7.5575	6168	7.5575	DE
52	0	0	7.5575	7.5575	7.5575	3843	7.5575	DE
156	0	0	7.5575	7.5575	7.5575	3872	7.5575	DE
260	0	0	7.5575	7.5575	7.5575	6602	7.5575	DE

0O2W - Frequently Asked Questions (FAQ)

What is the current GFT Technologies SE share price?

The current share price of GFT Technologies SE is 7.5575 €

How many GFT Technologies SE shares are in issue?

GFT Technologies SE has 25,564,808 shares in issue

What is the market cap of GFT Technologies SE?

The market capitalisation of GFT Technologies SE is EUR 193.21M

What is the 1 year trading range for GFT Technologies SE share price?

GFT Technologies SE has traded in the range of 7.5575 € to 7.5575 € during the past year

What is the PE ratio of GFT Technologies SE?

The price to earnings ratio of GFT Technologies SE is 15.94

What is the cash to sales ratio of GFT Technologies SE?

The cash to sales ratio of GFT Technologies SE is 0.61

What is the registered address of GFT Technologies SE?

The registered address for GFT Technologies SE is Schelmenwasenstrasse 34, Stuttgart, Baden-Württemberg, 70567

What is the GFT Technologies SE website address?

The website address for GFT Technologies SE is www.gft.com

Seminole Red

Seminole Red 2分前

PEACHMAN

PEACHMAN 4分前

I suggest people read your informative IFUS post again so that it makes sense with my comments

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177740678

YOU stated

If I were the interim CEO of IFUS right now, what would I do? Let's just set

Whalatane

Whalatane 5分前

UNCY's UniSource hub .
I suggest you all read up on this B2B plan UNCY is starting to make it really easy for dialysis centers to prescribe , store and bill for OLC .
Its designed to over come a lot of the hurdles , drug co's face launching new drugs into a field dominated by Freseniu

Zadie420

Zadie420 6分前

Exactly eagle8.
I think once we use DCVax-L plus Poly-ICLC, DCVax-D+ and aDC1 treatments in other cancer types we will see tremendous price movement.

porty

Well, I don’t have my shares yet so they are worth nothing. More optimistic now that I might actually get them.

gorbec1

gorbec1 9分前

Let the piggy bank eat .

The excitement builds

OracleWitch66

OracleWitch66 10分前

You as well aqua

OracleWitch66

OracleWitch66 11分前

Hell yeah kj thanks for all your DD much appreciated let's go FITY

Musical Shares

Musical Shares 11分前

In over 25 years

It's quite a feature, isn't it?

What seems to always be missing here is that RadioGel was NOT the first thermogel with a radionuclide. It's even in their "prior art" section on their original patent from 1998!

And there have been many oth

eagle8

eagle8 12分前

starric, as usual, thanks for your posts.

The ultimate goal for NWBO is, of course, DCvax-Direct.
With the Kalinski method, aDCs, we won't need many adjuvants anymore.
Then only the companies with the most necessary adjuvants will benefit.
And there aren't that ma

barnstormer

barnstormer 12分前

Brazen. Boilerplate noise no, but boilerplate regardless. It's regulatory language the company has to keep repeating until the regulator approves the product. When I noted the language was also written to protect the company from litigation, I was referring to the whole regulatory document. Its car

3331

$250K IS THE MAGIC NUMBER!
$250,000 profit will get the PPS to COPPER @ P/E = 1,000 (not unusual for stocks turning profitable for the first time and with increasing future growth/revenue/profit projections). This will happen when investors are confident the profit will be achieved, likely

jimr1717

jimr1717 14分前

16 years of the same Ruse. No one is Fooled

Investor2014

Investor2014 16分前

Also carefully read section 2.6.9. Discussion on clinical safety.

That safety discussion is not comparable to a normal approved-drug safety review where risks are identified, quantified, labelled and managed. CHMP found that blarcamesine’s safety package was too small for a large chr

CanadianInvestor1

CanadianInvestor1 17分前

Check video out at 3:55 and 5:11.

CanadianInvestor1

CanadianInvestor1 19分前

New CEO took over 1.5 years ago. Lots of trial data in the last year shows the efficacy of Revyve. Recent video says this is a good time for entry to the US market, due to changes in Medicare rules last year pushing skin subs (competitors to KNBIF) out of business. https://wallstreetanalyzer.com/202

William777

William777 19分前

Drilling down on JB statement, "NutraNomics looks forward to further collaboration announcements with RE Strategies in the near future."
What strategies are coming our way?

SSKILLZ1

SSKILLZ1 20分前

They win a game so the response is to rest lindor, sit aj ewing, and start mark vientos because he is so good defensively at 1b, at 3b he should even be better at this point, wagaman at 1b, baty at 2b, they could get the same result by simply forfeiting the game. And Kodai Senga who should have been

MONTI KING

MONTI KING 20分前

I think it’s important to keep in mind that givebux valued VitOrgan/ shop at 39 million almost two years ago.. that was for just 1 piece. VitOrgan decided not to complete the LOI.. and here we are!

The $39 million figure came directly from GivBux’s February 3, 2025, press release an

pos_stock_hoarder

pos_stock_hoarder 23分前

Gene Chandler - The Duke of Earl
https://youtu.be/Qa88gqvXJMc

cashclan

cashclan 23分前

Probably has nothing

To do with the bullet points.

Liquidity is drying up. No, Liquidity you get a crash. Happened in 1929.

July 4th Independency Day. Without Liquidity the old system has 3 days to critical mass of no return. Then 10 days of f

Drugdoctor

Drugdoctor 23分前

Sadly, you will probably still be bashing George and his companies until you are in the grave. It's pathetic to see you on all 4 boards with continuous posting even after George has passed. Can't you let him rest in peace?

Frank69OH

Frank69OH 25分前

GFT Technologies

Zealand Pharma AS

Cytek Biosciences

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。